a serine/threonine-protein kinase receptor for bone morphogenetic protein (BMP). Binds to BMP-7, BMP-2 and, less efficiently, BMP-4. Binding is weak but enhanced by the presence of type I receptors for BMPs. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Defects in BMPR2 are the cause of primary pulmonary hypertension (PPH1), a weakly penetrant dominant disorder, associated with lesions in pulmonary arterioles, elevated pulmonary arterial pressure, and right ventricular failure. Note: This description may include information from UniProtKB.
Protein type: Kinase, protein; Protein kinase, Ser/Thr (receptor); Cell cycle regulation; Membrane protein, integral; EC 126.96.36.199; Protein kinase, TKL; TKL group; STKR family; Type2 subfamily
Cellular Component: cell surface; integral to plasma membrane; plasma membrane; caveola
Molecular Function: transforming growth factor beta receptor activity; protein binding; metal ion binding; activin receptor activity, type II; ATP binding
Biological Process: transcription from RNA polymerase II promoter; regulation of lung blood pressure; negative regulation of systemic arterial blood pressure; cellular response to starvation; positive regulation of bone mineralization; negative regulation of vasoconstriction; regulation of cell proliferation; anterior/posterior pattern formation; BMP signaling pathway; positive regulation of osteoblast differentiation; mesoderm formation; lymphangiogenesis; transmembrane receptor protein serine/threonine kinase signaling pathway; blood vessel remodeling; positive regulation of endothelial cell proliferation; negative regulation of cell growth; vascular endothelial growth factor receptor signaling pathway; alveolus development; positive regulation of BMP signaling pathway
Alt. Names/Synonyms: BMP type II receptor; BMP type-2 receptor; BMPR-2; BMPR-II; BMPR2; BMPR3; BMPRII; BMR2; Bone morphogenetic protein receptor type II; Bone morphogenetic protein receptor type-2; bone morphogenetic protein receptor, type II (serine/threonine kinase); BRK-3; FLJ41585; FLJ76945; PPH1; T-ALK; type II activin receptor-like kinase; type II receptor for bone morphogenetic protein-4
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.